ArticleThe oncologist2018
Autologous Stem Cell Transplantation in Elderly Lymphoma Patients in Their 70s: Outcomes and Analysis.
Article in The oncologist, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 30 citations in OpenAlex.
- Trial
- Impact of age on outcomes after CD19 CAR T-cell therapy for large B-cell lymphomas.Blood neoplasia · 2026Article
- Lite-BEAM expands autologous stem cell transplantation access for older or unfit patients with lymphoma.Leukemia & lymphoma · 2025Article
- Reduced Intensity Conditioning Prior Autologous Stem Cell Transplantation in Elderly DLBCL Patients.European journal of haematology · 2025Article
- Cellular therapy in older adults with relapsed/refractory diffuse large B-cell lymphoma.Frontiers in oncology · 2024Review
- Re-examining the role of hematopoietic stem cell transplantation in relapsed large B-cell lymphoma in the era of chimeric antigen receptor (CAR) T-cell therapy.Frontiers in oncology · 2024Review
- The Treatment of Diffuse Large B-Cell Lymphoma (Triple Expression) Involving the Breast, Spleen, and Bone in a Male Patient with Viral Hepatitis B: A Rare Case Report.Cancer management and research · 2023Article
- Autologous stem cell transplantation in an older adult population.Haematologica · 2022Article
- Outcomes of Autologous Hematopoietic Cell Transplantation in Older Patients with Diffuse Large B-Cell Lymphoma.Transplantation and cellular therapy · 2022Article
- Dose-adjusted high-dose chemotherapy with autologous stem cell transplantation for elderly (≥ 70 years old) lymphoma patients.Annals of hematology · 2022Article
- Toxicities of high-dose chemotherapy and autologous hematopoietic cell transplantation in older patients with lymphoma.Blood advances · 2021Article
- Kidney injury and disease in patients with haematological malignancies.Nature reviews. Nephrology · 2021Review
- Long-term outcomes of older patients with relapsed/refractory NHL referred to ASCT.Bone marrow transplantation · 2021Article
- Hematopoietic-cell transplantation for lymphoma in the era of genetically engineered cellular therapy: it's not quite time to scrap the old vehicle for the new car.Current opinion in hematology · 2019Review
- [Efficiency and safety of autologous hematopoietic stem cell transplantation for 19 cases with elderly lymphoma].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2018Article
- Hematopoietic Cell Transplant (HCT) in the Elderly: Myths, Controversies and Unknowns.Drugs & aging · 2018Review
- How I manage patients with relapsed/refractory diffuse large B cell lymphoma.British journal of haematology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHigh-dose chemotherapy and autologous stem cell transplantation (ASCT) can offer durable remission in many patients with relapsed or high-risk lymphoma. However, elderly patients are often not considered ASCT candidates based on age alone. SUBJECTS, MATERIALS, AND
methodsA retrospective analysis of patients ≥70 years of age with a diagnosis of Hodgkin or non-Hodgkin lymphoma receiving ASCT between 2000 and 2016 at two partner institutions was performed. Clinical data were extracted from institutional databases and individual medical records. Multivariate analysis was performed to examine the association of clinical variables with transplant outcomes.
resultsOne hundred seven patients were identified. Median age at transplant was 72 years (range, 70-79). The most common lymphoma subtype was diffuse large B-cell (
conclusionEligibility for ASCT should be an individualized decision, and age should not be an absolute contraindication to ASCT in healthy elderly patients with lymphoma. IMPLICATIONS FOR PRACTICE: Although high-dose chemotherapy and autologous stem cell transplantation (ASCT) can offer durable remission in many patients with relapsed or high-risk lymphoma, elderly patients are often not considered candidates due to concern for excess toxicity and mortality. This retrospective study showed favorable transplant outcomes, including survival and toxicity, in a large cohort of lymphoma patients over 70 years of age who underwent ASCT. Eligibility for ASCT should be an individualized decision, and age should not be an absolute contraindication to ASCT in healthy elderly patients with lymphoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.